Last C$0.33 CAD
Change Today 0.00 / 0.00%
Volume 0.0
As of 9:30 AM 04/11/14 All times are local (Market data is delayed by at least 15 minutes).

welichem biotech inc (WBI) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/4/13 - C$0.75
52 Week Low
06/3/13 - C$0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WELICHEM BIOTECH INC (WBI)

Related News

No related news articles were found.

welichem biotech inc (WBI) Related Businessweek News

No Related Businessweek News Found

welichem biotech inc (WBI) Details

Welichem Biotech Inc., a development stage biotechnology company, engages in the discovery and development of therapeutic drugs for autoimmune diseases and cancers. Its lead drug candidate, WBI-2100, is in the pre-clinical stage of development to treat various cancerous tumors. The company is developing product candidates through its Symbiochem technology platform. Welichem Biotech Inc. is based in Burnaby, Canada.

welichem biotech inc (WBI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: C$107.0K
Chief Financial Officer and Secretary
Total Annual Compensation: --
Vice President of Research & Development
Total Annual Compensation: C$93.6K
Compensation as of Fiscal Year 2013.

welichem biotech inc (WBI) Key Developments

Welichem Announces Changes of Directors

Welichem Biotech Inc. announced that Ryan B. Zeng has been appointed as a new director of the company effective immediately. Mr. Zeng has been serving as a senior manager of T&T Supermarket in Richmond, British Columbia since 2008. He has extensive experience and knowledge in computer sciences, company operation and management from various industries including technology and supermarket companies over more than 15 years. Mr. Zeng obtained his Bachelors Degree in Computer Science from Jilin University (China) in 1998. The company also announced that Mr. James Dai has resigned as a director of the company effective January 2, 2014. The company has valued the contribution of Mr. Dai as a director of the company and Chair of the Audit Committee over the past year and wishes his success in his future endeavors.

Welichem Biotech Inc., Annual General Meeting, Nov 29, 2013

Welichem Biotech Inc., Annual General Meeting, Nov 29, 2013., at 10:00 Pacific Standard Time. Location: The offices of Fasken Martineau DuMoulin LLP. Agenda: To consider the audited financial statements of the company for the fiscal year ended May 31, 2013, and the accompanying report of the auditors; to set the number of directors of the company for the ensuing year at three; to elect Guoqing (Frank) Li, James Dai and Lei Lv as directors; to appoint Ernst & Young LLP, Chartered Accountants, as the auditors of the company at remuneration to be determined by the auditors; and to transact such further or other business as may properly come before the Meeting.

Welichem Biotech Inc. Announces the Resignation of Lijuan Pang as Director

Welichem Biotech Inc. announced that Mrs. Lijuan Pang has resigned as a director of the company effective March 1, 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WBI:CN C$0.33 CAD 0.00

WBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WBI.
View Industry Companies

Industry Analysis


Industry Average

Valuation WBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WELICHEM BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at